Honig LS, et al. - This trial was carried out in order to gauge the efficacy of solanezumab in the management of mild dementia owing to Alzheimer's disease. Data did not illustrate any notable impact of solanezumab, at a dose of 400 mg administered every 4 weeks, on the cognitive decline in patients with mild Alzheimer’s disease.